Core Viewpoint - Yahuang Pharmaceutical announced the election of Mr. Chen Baohua as the employee director of the company's second board of directors during the employee representative meeting scheduled for October 29, 2025 [1] Summary by Categories - **Company Announcement** - Yahuang Pharmaceutical will hold an employee representative meeting on October 29, 2025 [1] - Mr. Chen Baohua has been elected as the employee director of the second board of directors [1]

Core Insights - The company achieved a total operating revenue of 216 million yuan in the first three quarters of 2025, representing a year-on-year increase of 55.74% [1] - The net profit attributable to shareholders of the parent company was -249 million yuan, which is a reduction in losses by 21.89 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.44 yuan [1]

中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额置换的 核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"公司"或"上市公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《上海 证券交易所科创板股票上市规则》等相关规定，对公司使用自有资金支付募投项 目所需资金并以募集资金等额置换事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏亚虹医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕3797 号）同意注册，公司向社 会公开发行人民币普通股 11,000 万股，每股面值人民币 1 元，每股发行价为人 民币 22.98 元，募集资金总额为人民币 252,780.00 万元，实际募集资金净额为人 民币 238,059.22 万元。以上募集资金到位情况已经立信会计师事务所（特殊普通 合伙）审验并出具了《验资报告》（信会计师报字[2021]第 ZA15998 号）。 二、募投项目的基本情况 根据《江苏 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-040 江苏亚虹医药科技股份有限公司 关于选举第二届董事会职工董事及聘任高级管理人 员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开职工代表大会并做出决议，选举陈宝华先生为公司第二届董事会职工董事； 于同日召开第二届董事会第十九次会议，审议通过了《关于聘任高级管理人员的 议案》，同意聘任陈宝华先生为公司财务负责人、董事会秘书。现将相关情况公 告如下： 一、 职工董事的选举情况 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板股票上市规则》和《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）等法律法规、规范性文件的要求，公司于 2025 年 10 月 29 日召开职 工代表大会并做出决议，选举陈宝华先生（简历详见附件）为公司第二届董事会 职工董事，任期自公司职工代表大会决议之日起至第二届董事会任期届满之日止。 经公司董 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-041 江苏亚虹医药科技股份有限公司 关于使用自有资金支付募投项目所需资金并以募集 资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开第二届董事会第十九次会议，审议通过《关于使用自有资金支付募投项目 所需资金并以募集资金等额置换的议案》，同意公司（含实施募集资金投资项目 的子公司，下同）在募集资金投资项目（以下简称"募投项目"）实施期间，根 据实际情况使用自有资金支付募投项目所需资金，并以募集资金等额置换，从募 集资金专户划转等额资金至公司自有资金账户，该部分等额置换资金视同募投项 目使用资金。中信证券股份有限公司（以下简称"保荐人"）对本事项出具了明 确的核查意见。上述事项在董事会审批权限范围内，无需提交股东会审批。现将 相关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏亚虹医药科技股份有限公司首次 公开发行股票注册的批复》 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥86,170,827.01, representing a year-on-year increase of 47.41%[5] - The total profit for the period was a loss of ¥91,109,604.17, with a net profit attributable to shareholders of ¥-86,732,800.64[5] - Total revenue for the first three quarters of 2025 reached ¥216,408,302.14, a significant increase of 55.7% compared to ¥138,951,629.03 in the same period of 2024[21] - Net loss for the first three quarters of 2025 was ¥261,050,841.03, slightly improved from a net loss of ¥271,342,070.94 in the same period of 2024[22] - Basic earnings per share for the first three quarters of 2025 were -¥0.44, compared to -¥0.48 in the previous year[23] Research and Development - Research and development (R&D) expenses amounted to ¥53,359,320.94, which is a decrease of 17.96% compared to the previous year[6] - R&D expenses accounted for 61.92% of operating revenue in the current period, down by 49.34 percentage points year-on-year[6] - Research and development expenses were ¥169,848,302.99, a decrease of 22.4% from ¥219,040,308.86 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,148,699,982.48, a decrease of 3.34% from the previous year[6] - The net assets attributable to shareholders decreased by 11.42% to ¥1,744,502,159.34 compared to the end of the previous year[6] - Total assets decreased to ¥2,148,699,982.48 from ¥2,222,991,903.79, reflecting a decline of 3.3%[19] - Total liabilities increased to ¥412,493,308.25, up from ¥252,618,105.29, marking a rise of 63.4%[19] - The company's equity attributable to shareholders decreased to ¥1,744,502,159.34 from ¥1,969,405,336.09, a decline of 11.4%[19] Cash Flow - The company reported a net cash flow from operating activities of ¥-301,798,901.12 for the year-to-date period[5] - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $216.36 million, a significant increase from $128.58 million in the same period of 2024, representing a growth of about 68.2%[25] - The net cash flow from operating activities was negative at approximately -$301.80 million for 2025, compared to -$325.16 million in 2024, showing an improvement of about 7.1%[26] - The total cash outflow from operating activities was approximately $518.16 million in 2025, compared to $453.74 million in 2024, marking an increase of about 14.2%[26] Investments - Cash inflow from investment activities totaled approximately $4.56 billion in 2025, compared to $3.40 billion in 2024, indicating an increase of about 34.1%[26] - The net cash flow from investment activities was negative at approximately -$60.29 million in 2025, contrasting with a positive $443.76 million in 2024, reflecting a significant decline[26] - The company received approximately $8.07 million from investment in subsidiaries in 2025, while no such income was recorded in 2024[26] - The company reported a cash inflow from the recovery of investments of approximately $4.56 billion in 2025, compared to $3.40 billion in 2024, indicating a strong performance in investment recovery[26] Shareholder Information - The company has a total of 8,667,675 shares in its repurchase account, accounting for 1.52% of total shares[14] - The top shareholder, Pan-Scientific Holdings Co., Ltd., holds 31,858,481 shares, representing a significant portion of the company's equity[14] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[15] Financial Statements - The financial statements for the quarter are unaudited, indicating that the figures are subject to final review and adjustments[17]

Core Insights - On October 27, Yahui Pharmaceutical's stock rose by 1.43%, with a trading volume of 46.12 million yuan [1] - The company reported a financing buy-in of 3.43 million yuan and a financing repayment of 4.61 million yuan, resulting in a net financing outflow of 1.18 million yuan on the same day [1] - As of October 27, the total margin balance for Yahui Pharmaceutical was 194 million yuan, representing 4.49% of its market capitalization [1] Financing Overview - On October 27, Yahui Pharmaceutical had a financing buy-in of 3.43 million yuan, with a current financing balance of 194 million yuan, which is above the 70th percentile of the past year [1] - The company had no short-selling activity on October 27, with a short-selling balance of 0 yuan, indicating a high level of short-selling availability compared to the past year [1] Company Profile - Yahui Pharmaceutical, established on March 16, 2010, is located in the Pudong New Area of Shanghai and was listed on January 7, 2022 [1] - The company's main business involves the research, production, and sales of innovative drugs, with 96.34% of its revenue coming from anti-tumor products [1] Shareholder Information - As of June 30, the number of shareholders for Yahui Pharmaceutical was 25,500, an increase of 2.09% from the previous period [2] - The average number of circulating shares per shareholder decreased by 2.05% to 14,857 shares [2] - For the first half of 2025, Yahui Pharmaceutical reported a revenue of 130 million yuan, a year-on-year increase of 61.80%, while the net profit attributable to the parent company was -162 million yuan, an increase of 11.84% year-on-year [2] Institutional Holdings - As of June 30, 2025, the fourth largest circulating shareholder of Yahui Pharmaceutical was Penghua Medical Technology Stock A, holding 6.54 million shares, an increase of 891,300 shares from the previous period [2]

Core Viewpoint - The financial performance of Yahui Pharmaceutical (688176.SH) in the first half of 2025 shows significant revenue growth but continues to report net losses, indicating ongoing challenges in profitability despite increased sales [1][3]. Financial Performance - The company achieved operating revenue of 130.24 million yuan in the first half of 2025, representing a year-on-year increase of 61.80% compared to 80.49 million yuan in the same period last year [1][3]. - The net profit attributable to shareholders was -162.21 million yuan, an improvement from -183.99 million yuan in the previous year [1][3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -177.15 million yuan, compared to -196.91 million yuan in the same period last year [1][3]. - The net cash flow from operating activities was -194.27 million yuan, an improvement from -242.84 million yuan year-on-year [1][3]. Historical Performance - From 2018 to 2024, the net profit attributable to shareholders has shown a consistent trend of losses, with figures ranging from -59.93 million yuan in 2018 to -384 million yuan in 2024 [3]. - The net profit after deducting non-recurring gains and losses also reflects a similar trend, with losses increasing from -64.05 million yuan in 2018 to -409 million yuan in 2024 [3]. Company Background - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an initial issuance of 110 million shares at a price of 22.98 yuan per share [4]. - The stock price has been in a state of decline since its debut, with the highest price recorded at 20.00 yuan on the first trading day [4]. - The total funds raised from the initial public offering amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [4].

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. announced the publication of clinical trial results for its product APL-1702 in the international journal "Med," which is a flagship journal in the medical field under Cell Press [2][8]. Group 1: Product and Disease Information - APL-1702 is a photodynamic therapy product that combines drug and device for the treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) [3]. - According to the 2020 Global Cancer Statistics, there were 604,127 new cases of cervical cancer globally, with 341,831 deaths, making it the fourth most common malignancy among women [3]. - In China, cervical cancer ranks second among female malignancies, with 150,700 new cases and 55,700 deaths reported in 2022 [3]. Group 2: Clinical Trial Results - The international multicenter phase III clinical trial was randomized, double-blind, and placebo-controlled, involving 402 eligible patients from multiple countries [6]. - The primary efficacy endpoint was achieved, with the APL-1702 group showing an 89.4% higher response rate compared to the placebo group (41.1% vs. 21.7%, p = 0.0001) [6]. - The pathological regression rate for the APL-1702 group was significantly higher than that of the placebo group (47.0% vs. 29.5%, p < 0.001) [7]. - APL-1702 demonstrated a 103.90% increase in the clearance rate of high-risk HPV types 16/18 compared to the placebo group (31.4% vs. 15.4%, p = 0.011) [7]. - The overall response rate for the APL-1702 group reached 44.4% at the 12-month follow-up [7]. Group 3: Market Potential and Clinical Need - There is a significant unmet clinical need for non-surgical therapies for cervical precancerous lesions, as current treatments primarily involve invasive cervical excision [5]. - The treatment landscape for cervical precancerous lesions has seen slow progress, with no non-surgical products approved for HSIL based on phase III clinical trial efficacy [5]. - The number of diagnosed HSIL patients in China is expected to reach 1 million by 2030, indicating a growing market potential for APL-1702 [4].

证券代码：688176 证券简称：亚虹医药 公告编号：2025-039 江苏亚虹医药科技股份有限公司 自愿披露关于在 APL-1702 国际多中心Ⅲ期临床试验相 关数据获国际期刊《Med》发表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、近日，江苏亚虹医药科技股份有限公司（以下简称"公司"）产品 APL-1702 用于治疗宫颈高级别鳞状上皮内病变（High-Grade Squamous Intraepithelial Lesion, HSIL）的前瞻、随机、双盲、安慰剂对照的国际多中心Ⅲ期临床试验（以下简 称"本研究"）结果已获 Cell Press 旗下《Med》线上发表。《Med》系由 Cell Press 创立，是继《Cell》《Chem》后，Cell Press 推出的医学领域旗舰刊，属于 Journal Citation Reports（JCR）Q1、中科院双一区的 TOP 期刊。 2、目前上述产品尚处于国家药品监督管理局药品审评中心审评审批阶段， 上述产品能否成功上市及上市时间具有 ...